SEC Form 4 · accession 0001859453-26-000014
Vera Therapeutics, Inc. · VERA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Marshall Fordyce
Officer — PRESIDENT AND CEO · Director
Period of report
Sep 2, 2026
Accepted (ET)
Sep 4, 2026 · 4:15 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001831828
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Class A Common Stock | Sep 2, 2026 | M | 18,500 | $2.8968 | A | 253,744 | D | |
| Class A Common StockF2 | Sep 2, 2026 | S | 18,500 | $35.1158 | D | 235,244 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F3 | $2.8968 | Sep 2, 2026 | M | 18,500 | D | — | Dec 15, 2030 | Class A Common Stock | 18,500 | 507,301 | D |
Explanation of responses
- F1The sales were made pursuant to a written plan adopted on January 9, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended.
- F2The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $35.00 to $35.34, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price.
- F31/4 of the shares subject to the option vested on December 16, 2021, and 1/48 of the shares vested monthly thereafter.